Our findings anticipate a promising outcome with the administration of Hiltonol (polyI:C-based therapy), either alone or in combination with siltuximab (anti-IL6 monoclonal antibody) and/or STAT3/ JAK2 antagonists, for treatment of lung cancers, particularly, the subtypes which express low-to-medium levels of TLR3 protein. The gene discussed is TLR3; the disease is lung carcinoma.